1.
Aust J Gen Pract
; 53(3): 138-140, 2024 03.
Article
in English
| MEDLINE
| ID: mdl-38437657
2.
Australas J Dermatol
; 64(1): 131-137, 2023 Feb.
Article
in English
| MEDLINE
| ID: mdl-36514287
ABSTRACT
We present a case series of 13 patients, the first Australian single-centre study of bullous pemphigoid (BP) associated with immune checkpoint inhibitors (ICI): cytotoxic T-lymphocyte antigen (CTLA4) and programmed cell death receptor (PD1) inhibitors. All our patients achieved adequate control of BP with a combination of treatments including oral prednisolone, intravenous immunoglobulin, rituximab and omalizumab. The majority of patients ceased or interrupted immunotherapy treatment upon diagnosis of BP and greater tumour progression was seen in the cohort who ceased immunotherapy.
Subject(s)
Immune Checkpoint Inhibitors , Pemphigoid, Bullous , Humans , Australia , B7-H1 Antigen/drug effects , Cell Death , Pemphigoid, Bullous/etiology , Pemphigoid, Bullous/pathology , Immune Checkpoint Inhibitors/adverse effects , Immune Checkpoint Inhibitors/therapeutic use
3.
Aust Fam Physician
; 46(10): 744-745, 2017 Oct.
Article
in English
| MEDLINE
| ID: mdl-29036774